Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $8.9 million.

  • Beam Therapeutics' Capital Expenditures rose 217.76% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year increase of 48.27%. This contributed to the annual value of $8.9 million for FY2024, which is 73.48% down from last year.
  • Latest data reveals that Beam Therapeutics reported Capital Expenditures of $8.9 million as of FY2024, which was down 73.48% from $33.7 million recorded in FY2023.
  • In the past 5 years, Beam Therapeutics' Capital Expenditures registered a high of $49.0 million during FY2022, and its lowest value of $8.9 million during FY2024.
  • Over the past 3 years, Beam Therapeutics' median Capital Expenditures value was $33.7 million (recorded in 2023), while the average stood at $30.5 million.
  • As far as peak fluctuations go, Beam Therapeutics' Capital Expenditures spiked by 186.18% in 2021, and later plummeted by 73.48% in 2024.
  • Beam Therapeutics' Capital Expenditures (Yearly) stood at $16.4 million in 2020, then spiked by 186.18% to $46.8 million in 2021, then increased by 4.57% to $49.0 million in 2022, then crashed by 31.09% to $33.7 million in 2023, then plummeted by 73.48% to $8.9 million in 2024.